A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fasting condition in healthy volunteers.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Sequence 1 Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202 |
Drug: HCP2202
Take it once per period.
Drug: RLD2202
Take it once per period.
Drug: RLD2203
Take it once per period.
|
Experimental: Sequence 2 Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203 |
Drug: HCP2202
Take it once per period.
Drug: RLD2202
Take it once per period.
Drug: RLD2203
Take it once per period.
|
Outcome Measures
Primary Outcome Measures
- AUCt [0~24 hours]
Pharmacokinetic evaluation
- Cmax [0~24 hours]
Pharmacokinetic evaluation
Secondary Outcome Measures
- AUCinf [0~24 hours]
Pharmacokinetic evaluation
- Tmax [0~24 hours]
Pharmacokinetic evaluation
- t1/2 [0~24 hours]
Pharmacokinetic evaluation
- CL/F [0~24 hours]
Pharmacokinetic evaluation
- Vd/F [0~24 hours]
Pharmacokinetic evaluation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 19~54 years in healthy volunteers 18.5 kg/m2 ≤ BMI < 30 kg/m2, weight(men) ≥55kg / weight(women) ≥45kg
-
90 mmHg ≤ SBP <140 mmHg, 50 mmHg ≤ DBP <90 mmHg
-
agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug.
-
Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial
Exclusion Criteria:
-
Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
-
Subjects who judged ineligible by the investigator
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Chonbuk National University Hospital | Jeonju | Jeollabuk-do | Korea, Republic of |
Sponsors and Collaborators
- Hanmi Pharmaceutical Company Limited
Investigators
- Principal Investigator: Mingul Kim, MD, Jeonbuk National University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HM-SARA-102